Price to Earnings of Takeda Pharm

A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z

Price to Earnings analysis of Takeda Pharm


 Price 3,883.00  JPY
 Earnings per share 204.37  JPY
 Capitalization (mn) 5,903,056  JPY
 Net income (mn) 317,795  JPY
 P/E ratio 19.00
 Takeda Pharm dividend
 Takeda Pharm Price to book Value
 Takeda Pharm Price to Cash-Flow
 Takeda Pharm Return on Equity

Takeda Pharm is a Health Care industry firm, which concentrates their activity in the Pharmaceuticals and Biotechnology sector. Takeda Pharm headquarters are in Japan, where the firm is listed.

At the time of this analysis, Takeda Pharm stocks were trading at a price of 3,883.00 JPY after hiking a 17.40% last month.

According to the chart, Takeda Pharm has Price to Earnings ratio of 19.00, which is higher than the amount show in companies from Japan. However, it is lower than the average of Pharmaceuticals and Biotechnology sector. The company should be deeply studied because P/E ought to be quite similar among firms from the same sector unless they carry a very different strategy. Thus, Takeda Pharm financial report should be analyzed to confirm the company is undervalued.

Finally, you could compare Takeda Pharm P/E with other Pharmaceuticals and Biotechnology companies or firms from Japan.

Takeda Pharm price to earnings

Next companies

TAL Education Group. China. Consumer Services.

Talaat Moustafa Grou. Egypt. Financials.

Talanx AG. Germany. Financials.

Tambang Batubara Buk. Indonesia. Basic Materials.

T&D Holdings. Japan. Financials.

Tapestry. USA. Consumer Goods.

Previous companies

Take-Two Interactive Software. USA. Consumer Goods.

Takashimaya. Japan. Consumer Services.

Takara Holdings. Japan. Consumer Goods.

Takara Bio. Japan. Health Care.

Taiyo Yuden. Japan. Industrials.

Taiyo Nippon Sanso. Japan. Basic Materials.

All rights reserved

 information advertisement legal

Dividends Ranking | Price to BookValue | Price to Cash-Flow | Price to Earnings | Return on Equity

Part of Enciclopedia Financiera Group

Disclaimer: Information on this site is only for informational purposes. Always consult a professional advisor before investing.